Yoichi Nakayama, Akira Onishi, Wataru Yamamoto, Ayaka Yoshikawa, Hideyuki Shiba, Naofumi Yoshida, Yonsu Son, Iku Shirasugi, Toshihisa Maeda, Masao Katsushima, Motomu Hashimoto, Yuki Etani, Tetsu Itami, Yuji Nozaki, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Shuichi Matsuda, Akio Morinobu
Data on the safety of Janus kinase inhibitors (JAKis) in patients with renal impairment are lacking. This study aimed to investigate the safety of JAKis compared to biological (b) DMARDs in patients with rheumatoid arthritis (RA) and renal impairment. We used a multi-centre observational registry of patients with RA in Japan (the ANSWER cohort). We assessed the drug retention rates of b/targeted synthetic DMARDs with different modes of action (tumour necrosis factor inhibitors (TNFis), immunoglobulins fused with cytotoxic T-lymphocyte antigen (CTLA-4-Ig), interleukin-6 receptor inhibitors (IL-6Ris), and JAKis) in patients with RA stratified by pre-treatment estimated glomerular filtration rate (eGFR) levels...
May 10, 2024: Clinical and Experimental Medicine